BeOne's Liver Cancer Drug Shows 36% Response Rate in Phase 1 Trial
BeOne Medicines' BGB-B2033 demonstrates promising efficacy in liver cancer with a 36% response rate and 74.1% durability at the target dose.
BeOne Medicines' BGB-B2033 demonstrates promising efficacy in liver cancer with a 36% response rate and 74.1% durability at the target dose. Bitget Token (BGB) is trading at ₹179 ($1.88). This is an original Token Times brief based on reporting by Blockonomi, with live market data added, as of Sun, 25 Oct 2026 03:30:01 UTC.
The strong response rate and durability of BeOne's drug could position it as a significant breakthrough in liver cancer treatment, potentially improving patient outcomes and expanding treatment options.
- BGB-B2033 shows a 36% response rate in liver cancer patients.
- Six-month response durability rate at target dose is 74.1%.
- ONC shares dipped 1.21% despite positive clinical results.
- Roche's Phase 3 Kidney Drug Trial Boosts Stock 2.60% Amid AI Market Turmoil
- BeOne's Liver Cancer Drug Shows 36% Response Rate in Phase 1 Trial — this brief
BeOne Medicines AG has reported positive results from its Phase 1 clinical study of BGB-B2033, a drug targeting liver cancer, with a 36% response rate. The study also showed a 74.1% six-month response durability rate at the target dose, indicating promising potential for long-term efficacy.
In addition to the liver cancer results, BeOne's lung cancer ADC delivered a 56% response rate in patients with CEA-high tumors. The company's PRMT5 inhibitor, BGB-58067, recorded a 30.8% intracranial response rate in lung cancer patients, further highlighting the company's advancements in oncology treatments.
Despite the positive clinical results, shares of BeOne Medicines (ONC) slipped by 1.21%, suggesting potential market skepticism or profit-taking following the announcement.
The broader crypto market remains relatively stable, with a total market cap of $2.77 trillion and a Fear & Greed Index of 54, indicating a neutral sentiment. The price of 
Bitget Token (BGB), which is not directly related to BeOne Medicines, is $1.88, with a 24-hour decrease of 0.64%.
The strong clinical results for BGB-B2033 could position BeOne Medicines as a key player in the liver cancer treatment market. Investors and industry observers will likely monitor the progress of this drug in subsequent trials to assess its long-term potential.
Since this brief published about 18 hours ago, Bitget Token (BGB) has moved from ₹178.60$1.88 to ₹178.60$1.88 — +0.00%.
The chart plots BGB's price: grey is the move before this brief published, the vertical dashed line marks the moment it published, the horizontal dashed line is the price then, and the coloured area is the move since — from Token Times's market data (daily resolution). It shows what happened after the news, not that the news caused it; many factors move prices. Not financial advice.
At today's peer-to-peer rate, 1 BGB ≈ ₹194.76 (about $1.88), down 1.1% over 24 hours. The rupee itself trades about 9.0% above the official rate on the P2P market, so a Indian buyer's effective cost differs from the headline dollar price.
Live market data
Current prices for the asset in this story — live, source-stamped, updated every 15 minutes.
Figures and sectors in this story, checked live against on-chain aggregators · October 25, 2026.
Token Times reads these figures directly from on-chain aggregators (DeFiLlama, mempool.space) at build time — independent of what any outlet reported. Sector totals aggregate every protocol DeFiLlama tracks in that category. Values are live and will change.
BeOne's Liver Cancer Drug Shows 36% Response Rate in Pha — questions & answers
What is the response rate of BeOne's liver cancer drug?
The response rate of BeOne's BGB-B2033 in liver cancer patients is 36%.
What is the six-month response durability rate of BGB-B2033?
The six-month response durability rate of BGB-B2033 at the target dose is 74.1%.
How did ONC shares react to the clinical results?
ONC shares slipped by 1.21% despite the positive clinical results.
How much is 1 Bitget Token worth in rupee today?
About ₹194.76 at the live peer-to-peer (P2P) USDT rate, which is what Indians typically trade at — equivalent to roughly $1.88. The rupee price moves with both BGB's US-dollar price and the USDT/INR rate; use our Bitget Token in rupee page for any amount.
Which outlets reported this story?
This is an original Token Times brief that synthesises reporting from Blockonomi. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original Token Times brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.